AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) Director David Epstein acquired 14,980 shares of the stock in a transaction that occurred on Friday, November 13th. The stock was purchased at an average price of $5.92 per share, for a total transaction of $88,681.60. Following the completion of the purchase, the director directly owned 54,980 shares in the company, valued at $325,481.60. This trade represents a 37.45% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
AgomAb Therapeutics Stock Down 6.1%
NASDAQ AGMB opened at $5.97 on Tuesday. AgomAb Therapeutics NV has a 52 week low of $5.73 and a 52 week high of $17.82. The firm’s 50-day simple moving average is $9.38 and its two-hundred day simple moving average is $11.70.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on AGMB shares. Cantor Fitzgerald began coverage on shares of AgomAb Therapeutics in a research note on Wednesday, August 19th. They issued an “overweight” rating for the company. B. Riley Financial started coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target on the stock. Wall Street Zen downgraded shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Piper Sandler started coverage on shares of AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.50.
Read Our Latest Research Report on AGMB
About AgomAb Therapeutics
Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis. The company’s pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-β receptor ALK5 being developed for fibrostenotic Crohn’s disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis.
Read More
- Five stocks we like better than AgomAb Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
